NJ plans for new ACO

A new accountable care organization (ACO) is slated to go live on Sept. 1 in New Jersey.

The state's largest hospital healthcare delivery systemeight-hospital Barnabas Healthand the state's largest health insurerHorizon Blue Cross Blue Shieldhave partnered to launch the new care delivery model.

Under this ACO agreement, officials say Horizon BCBSNJ will extend care coordination payments to the ACO, taking on accountability for improving the health, patient experience and controlling the cost of care for its Horizon BCBSNJ Medicare Advantage patients. The ACO and its affiliated practices have an opportunity to share in the resulting savings, provided the ACO meets certain health improvement, patient satisfaction and cost goals.

This collaboration with Barnabas Health, through its affiliated accountable care organizations, Barnabas Health ACO-North and Central Jersey ACO, marks the health insurer's fifth ACO or population health initiative to launch within the past year. More than 320,000 members and 1,400 doctors are participating in Horizon BCBSNJ’s patient-centered programs.

"Collectively, these accountable care innovations inject a new level of collaboration and quality standards into our health delivery system and help remove wasteful, unnecessary costs," said Jim Albano, vice president of network and Horizon Healthcare Innovations, Horizon BCBSNY, in a release.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.